Biovica International AB (publ) (BIOVIC_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone and welcome to the Bayer-Vika Q1 interim report. Today I'll be presenting, me being Anders Rylander, together with my CFO Anders Morén. And we will be presenting according to this agenda. First, a short introduction about the company and the product. We'll go through the highlights of Q1. And Anders will do a financial update before a summary, and then we open up for a Q&A session. And the Q&A session will be done that way that we will start with Johanna Nerus, our analyst from Redeye, who will ask questions. in the meeting and everyone else listening also has a chance to ask question by submitting them into the chat function and you can remain anonymous if you want to by checking that checkbox and we will answer as many as possible of the questions that we get during the meeting and also If we're not able to answer all of them, we typically answer them in writing and put them at the end of the presentation that will be published after the meeting. So a few words about our product DIVITUM. So with DIVITUM, we measure cell proliferation. And as you all know, cell proliferation is what defines cancer or at least uncontrolled cell proliferation. We do that through a simple blood test that has a lot of advantages, especially when we are monitoring with several blood tests over time to make sure that the patient is on an effective treatment. And if not, it could be switched to an alternative treatment or an alternative dose in order to get the best possible treatment outcome of its cancer treatment. These patients are typically monitored today using image diagnostics, and we have in clinical trials shown that we can provide several advantages compared to imaging, both more convenient, but also quicker feedback by using DIVITUM for monitoring. This has been ...